# Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

> **NCT00437645** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1183 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Valsartan 160 mg capsules
- **DRUG:** Amlodipine 5 mg capsules
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00437645
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 1183 (ACTUAL)
- **Last updated:** 2014-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437645, "Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00437645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*